Biocon Foundation bags 'IHW Gold Award for Diseases Screening Initiative of the Year' for 2022

Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India

Lonza collaborates Cristal Therapeutics and McSAF to expand Bioconjugates offering

Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates

GeneQuantum and WuXi XDC enter into strategic cooperation to empower innovative bioconjugates development

WBF signs MOU with Sharda University to help advance biocontrol sector

Biocon initiates clinical study of Itolizumab for ulcerative colitis in India

This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study

Peter Bains appointed Additional Director of Biocon

He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels

Biocon Biologics elevates Shreehas Tambe as MD & CEO

Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.

Lonza collaborates with AbTis to extend Bioconjugation capabilities

Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox

Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business

To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan

Biocon enters commercialization agreement with Zentiva

Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe